
-
Lava Therapeutics NasdaqGS:LVTX LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands.
Location: Yalelaan 62, Utrecht, 3584 CM, Netherlands | Website: https://www.lavatherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-31.39M
Cash
66.56M
Avg Qtr Burn
-7.587M
Short % of Float
0.87%
Insider Ownership
32.69%
Institutional Own.
36.96%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LAVA-1266 Details Cancer, Hematologic malignancies, Acute myeloid leukemia, Myelodysplastic syndrome | Phase 1 Data readout | |
LAVA-1223 (SGN-EGFRd2) Details Cancer, Solid tumor/s | Phase 1 Update | |
LAVA-1207 Details Solid tumor/s, Cancer, Prostate cancer, Castration-resistant prostate cancer, Prostate disease | Failed Discontinued | |
LAVA-051 ( gamma-delta bsTCE targeting CD1d-expressing tumors) Details Solid tumor/s, Cancer, Chronic lymphocytic leukemia, Acute myeloid leukemia, Multiple myeloma | Failed Discontinued |